654 Nuclear envelope rupture and repair during cancer cell migration.
http://science.sciencemag.org/content/352/6283/353
653 Augmenting drug–carrier compatibility improves tumour nanotherapy efficacy.
http://www.nature.com/ncomms/2016/160413/ncomms11221/full/ncomms11221.html
652 Chemopreventive Metabolites Are Correlated with a Change in Intestinal Microbiota Measured in A-T Mice and Decreased Carcinogenesis.
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0151190
651 One-Shot Immunomodulatory Nanodiamond Agents for Cancer Immunotherapy.
http://onlinelibrary.wiley.com/doi/10.1002/adma.201506232/full
650 SCS macrophages suppress melanoma by restricting tumor-derived vesicle–B cell interactions.
http://science.sciencemag.org/content/352/6282/242
649 MYC regulates the antitumor immune response through CD47 and PD-L1.
http://science.sciencemag.org/content/352/6282/227
648 Repression of GSK3 restores NK cell cytotoxicity in AML patients.
http://www.nature.com/ncomms/2016/160404/ncomms11154/full/ncomms11154.html
647 Potentiating the antitumour response of CD8+ T cells by modulating cholesterol metabolism.
http://www.nature.com/nature/journal/v531/n7596/full/nature17412.html
646 Voluntary Running Suppresses Tumor Growth through Epinephrine- and IL-6-Dependent NK Cell Mobilization and Redistribution.
http://www.cell.com/cell-metabolism/fulltext/S1550-4131(16)30003-1
645 ELL targets c-Myc for proteasomal degradation and suppresses tumour growth.
http://www.nature.com/ncomms/2016/160324/ncomms11057/full/ncomms11057.html
644 Tracing the fate of circulating tumour cells by intravital two-photon lung imaging shows that tumours produce microparticles as they arrive and these migrate along the lung vasculature and are mostly taken up by interstitial myeloid cells, in a process that contributes to metastatic seeding; a minor subset of microparticles is engulfed by conventional dendritic cells, which are thought to contribute to the initiation of an anti-tumour immune response in lung-draining lymph nodes.
http://www.nature.com/nature/journal/v531/n7595/full/nature16985.html
643 A known oncogene, MITF, resides in a region of chromosome 3 that is amplified in melanomas and associated with poor prognosis; now, a long non-coding RNA gene, SAMMSON, is shown to also lie in this region, to also act as a melanoma-specific survival oncogene, and to be a promising therapeutic target for anti-melanoma therapy.
http://www.nature.com/nature/journal/v531/n7595/full/nature17161.html
642 Deletions linked to TP53 loss drive cancer through p53-independent mechanisms.
http://www.nature.com/nature/journal/v531/n7595/full/nature17157.html
641 Dendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell–driven rejection of high-grade glioma.
http://stm.sciencemag.org/content/8/328/328ra27.abstract
640 Tumor-initiating cells differentiate to a more benign state when treated with drugs that activate protein kinase A.
http://science.sciencemag.org/content/351/6277/aad3680
639 High-fat diet enhances stemness and tumorigenicity of intestinal progenitors.
http://www.nature.com/nature/journal/v531/n7592/full/nature17173.html
638 Tailoring nanoparticle designs to target cancer based on tumor pathophysiology.
http://www.pnas.org/content/113/9/E1142.abstract
637 Toll-like receptor-5 agonist, entolimod, suppresses metastasis and induces immunity by stimulating an NK-dendritic-CD8+ T-cell axis.
http://www.pnas.org/content/113/7/E874.abstract
636 Identification of a small molecule inhibitor of 3-phosphoglycerate dehydrogenase to target serine biosynthesis in cancers.
http://www.pnas.org/content/113/7/1778.abstract
635 Integrated nanotechnology platform for tumor-targeted multimodal imaging and therapeutic cargo release.
http://www.pnas.org/content/113/7/1877.abstract
|
